The company's related persons told Shanghai SecuritiesAccording to a reporter from the newspaper, the company submitted a registration application for albumin paclitaxel in Oman in January this year, received the registration approval notice only six months later, and recently obtained the official approval document.
　　In recent years, Sinovac BiotechThe company continues to deepen its international presence, focusing on building a high-quality global pharmaceutical export platform with "global product selection and global coverage." The company has established stable partnerships with numerous renowned domestic and international pharmaceutical companies, while also strengthening its overseas localized operations team, building comprehensive international capabilities encompassing overseas market insights, efficient registration applications, and targeted marketing and promotion.
　　The company's registration process in the Gulf Cooperation Council (GCC) member states is progressing steadily. Oman was the first to receive approval thanks to its efficient progress. The registration process in markets such as the UAE and Kuwait has also entered a critical phase, with further breakthroughs expected in the near future.
　　"With the company's first breakthrough in the Oman market, it can further radiate to GCC member countries and surrounding Middle East markets. The overseas commercialization prospects of albumin paclitaxel will continue to be released, and it is expected to contribute to the company's international business." The aforementioned person from the company said.
https://finance.eastmoney.com/a/202509053506404266.html